CH622702A5 - - Google Patents
Download PDFInfo
- Publication number
- CH622702A5 CH622702A5 CH1487975A CH1487975A CH622702A5 CH 622702 A5 CH622702 A5 CH 622702A5 CH 1487975 A CH1487975 A CH 1487975A CH 1487975 A CH1487975 A CH 1487975A CH 622702 A5 CH622702 A5 CH 622702A5
- Authority
- CH
- Switzerland
- Prior art keywords
- virus
- cat
- vol
- cats
- feline
- Prior art date
Links
- 241000282326 Felis catus Species 0.000 claims description 64
- 241000714201 Feline calicivirus Species 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 48
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 229960005486 vaccine Drugs 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 230000002238 attenuated effect Effects 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 230000000644 propagated effect Effects 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims 5
- 241000709664 Picornaviridae Species 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 208000031504 Asymptomatic Infections Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000006339 Caliciviridae Infections Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 231100000517 death Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000036732 histological change Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000026425 severe pneumonia Diseases 0.000 claims 1
- 206010041232 sneezing Diseases 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 8
- 239000007788 liquid Substances 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 241000282324 Felis Species 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- NAHBVNMACPIHAH-HLICZWCASA-N p-ii Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC2=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)=O)C(C)C)C1=CC=CC=C1 NAHBVNMACPIHAH-HLICZWCASA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/819—Viral vaccine for feline species, e.g. cats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/525,689 US3944469A (en) | 1974-11-21 | 1974-11-21 | Feline calicivirus vaccine and production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH622702A5 true CH622702A5 (ja) | 1981-04-30 |
Family
ID=24094242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1487975A CH622702A5 (ja) | 1974-11-21 | 1975-11-17 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3944469A (ja) |
| JP (1) | JPS5173118A (ja) |
| AT (1) | AT340584B (ja) |
| AU (1) | AU508944B2 (ja) |
| BE (1) | BE835784A (ja) |
| CA (1) | CA1055844A (ja) |
| CH (1) | CH622702A5 (ja) |
| DE (1) | DE2552137A1 (ja) |
| DK (1) | DK141339B (ja) |
| ES (1) | ES442892A1 (ja) |
| FI (1) | FI53593C (ja) |
| FR (1) | FR2291766A1 (ja) |
| GB (1) | GB1522006A (ja) |
| NL (1) | NL7513644A (ja) |
| NO (1) | NO753676L (ja) |
| SE (1) | SE7512828L (ja) |
| ZA (1) | ZA757294B (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287178A (en) * | 1974-03-25 | 1981-09-01 | Pitman-Moore, Inc. | Feline rhinotracheitis vaccine and production and use thereof |
| JPS5576819A (en) * | 1978-11-30 | 1980-06-10 | Wellcome Found | Attenuated feline infectious peritonitis virus |
| US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
| US4303645A (en) * | 1980-04-18 | 1981-12-01 | Cornell Research Foundation, Inc. | Modified living canine parvovirus vaccine |
| US4537769A (en) * | 1982-04-06 | 1985-08-27 | American Cyanamid Company | Stabilization of influenza virus vaccine |
| US4522810A (en) * | 1982-12-09 | 1985-06-11 | The Regents Of The University Of California | Feline calicivirus vaccine |
| US5374424A (en) * | 1986-10-03 | 1994-12-20 | Miles Inc. | Multivalent felv-infected feline vaccine |
| ATE193725T1 (de) * | 1992-02-28 | 2000-06-15 | Chemo Sero Therapeut Res Inst | Anti-felincalicivirus rekombinanter antikörper und dafür kodierendes gen |
| WO2000076538A1 (en) | 1999-06-10 | 2000-12-21 | Michigan State University | Feline calicivirus isolated from cat urine and vaccines thereof |
| US7309495B2 (en) * | 2003-03-14 | 2007-12-18 | The Regents Of The University Of California | Hemorrhagic feline calicivirus |
| CA2513458C (en) * | 2003-03-14 | 2013-01-22 | The Regents Of The University Of California | Virulent systemic feline calicivirus |
| US7306807B2 (en) | 2004-09-13 | 2007-12-11 | Wyeth | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease |
| WO2007012944A2 (en) * | 2005-07-28 | 2007-02-01 | Pfizer Products Inc. | Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus |
| MX2009013030A (es) * | 2007-05-30 | 2010-03-25 | Wyeth Llc | Poxvirus de mapache que expresa genes de antigenos felinos. |
| US10188725B2 (en) | 2015-12-14 | 2019-01-29 | Elanco Us Inc. | Hybrid core feline vaccines |
| CN114874997B (zh) * | 2022-05-26 | 2023-05-23 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 猫杯状病毒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1177635A (en) * | 1966-02-18 | 1970-01-14 | Wellcome Found | Cell Stains. |
-
1974
- 1974-11-21 US US05/525,689 patent/US3944469A/en not_active Expired - Lifetime
-
1975
- 1975-10-30 GB GB45026/75A patent/GB1522006A/en not_active Expired
- 1975-11-03 NO NO753676A patent/NO753676L/no unknown
- 1975-11-14 SE SE7512828A patent/SE7512828L/xx not_active Application Discontinuation
- 1975-11-17 CH CH1487975A patent/CH622702A5/de not_active IP Right Cessation
- 1975-11-17 DK DK516975AA patent/DK141339B/da unknown
- 1975-11-19 AU AU86755/75A patent/AU508944B2/en not_active Expired
- 1975-11-19 JP JP50138275A patent/JPS5173118A/ja active Pending
- 1975-11-20 DE DE19752552137 patent/DE2552137A1/de not_active Withdrawn
- 1975-11-20 AT AT884975A patent/AT340584B/de active
- 1975-11-20 FI FI753274A patent/FI53593C/fi not_active IP Right Cessation
- 1975-11-20 FR FR7535498A patent/FR2291766A1/fr active Granted
- 1975-11-20 BE BE162051A patent/BE835784A/xx unknown
- 1975-11-20 ZA ZA757294A patent/ZA757294B/xx unknown
- 1975-11-20 CA CA240,138A patent/CA1055844A/en not_active Expired
- 1975-11-21 NL NL7513644A patent/NL7513644A/xx not_active Application Discontinuation
- 1975-11-21 ES ES442892A patent/ES442892A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT340584B (de) | 1977-12-27 |
| ES442892A1 (es) | 1977-08-16 |
| AU8675575A (en) | 1977-05-26 |
| ZA757294B (en) | 1977-06-29 |
| NL7513644A (nl) | 1976-05-25 |
| BE835784A (fr) | 1976-05-20 |
| US3944469A (en) | 1976-03-16 |
| CA1055844A (en) | 1979-06-05 |
| AU508944B2 (en) | 1980-04-17 |
| GB1522006A (en) | 1978-08-23 |
| JPS5173118A (ja) | 1976-06-24 |
| DK516975A (ja) | 1976-05-22 |
| FR2291766B1 (ja) | 1978-07-28 |
| FI53593B (ja) | 1978-02-28 |
| DK141339B (da) | 1980-02-25 |
| FR2291766A1 (fr) | 1976-06-18 |
| DE2552137A1 (de) | 1976-05-26 |
| FI753274A (ja) | 1976-05-22 |
| ATA884975A (de) | 1977-04-15 |
| DK141339C (ja) | 1980-08-25 |
| NO753676L (ja) | 1976-05-24 |
| FI53593C (fi) | 1978-06-12 |
| SE7512828L (sv) | 1976-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH622702A5 (ja) | ||
| DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
| DE2516274C2 (de) | Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes | |
| DE2708668A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| US3937812A (en) | Feline calicivirus vaccine and production thereof | |
| DE69216732T2 (de) | Impfstoff gegen den Geflügelanämieerreger | |
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE2713371A1 (de) | Impfstoff gegen die rhinotracheitis der katze und verfahren zu seiner herstellung | |
| DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
| DE2362067C2 (de) | Temperaturempfindliche, nicht-pathogene, infektiöse Rinder-Rhinotracheitis-Virusstämme, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Lebendimpfstoffen | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| DE69835424T2 (de) | Boviner atmungs- und darmcoronavirus als impfstoff | |
| DE2120929B2 (de) | Lagerbeständiger Lebendimpfstoff zum Immunisieren von Hühnerküken gegen die Marek'sche Hühnerlähme | |
| DE2553998C2 (de) | Mumpsvaccin und Verfahren zu seiner Herstellung | |
| CH658192A5 (de) | Tollwut-impfstoff und verfahren zu seiner herstellung. | |
| DE2538994A1 (de) | Bakterieller impfstoff und verfahren zu seiner herstellung | |
| CH618091A5 (en) | Method for the attenuation of virulent feline rhinotracheitis virus and use of this virus for the production of a vaccine | |
| DE69014974T2 (de) | Impfstoff gegen Hundecoronavirus. | |
| DE3878982T2 (de) | Abgeschwaechtes virus und impfstoffe davon zur verwendung gegen infektionen bei gefluegel, verursacht durch truthahn-rhinotracheitis-virus. | |
| DE2058645C2 (de) | Verfahren zur Herstellung eines stark abgeschwächten Newcastle-Disease-Virus-Lebendimpfstoffs | |
| DE2805311A1 (de) | Respiratorische synzytial-vakzine | |
| DE2162013C3 (de) | Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut | |
| DE1021128B (de) | Verfahren zur Herstellung eines Impfstoffes gegen die Rhinotracheitis der Rinder | |
| CH629962A5 (de) | Verfahren zur herstellung einer vaccine gegen die panleukopenie der katze. | |
| WO1989005154A1 (en) | Process for producing an avirulent cold blood virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |